Regional Access Manager
About the job
- A university degree in Pharmacy, Life Sciences, Health Economics, or a related scientific discipline.
- Experience in a Regional Market Access, Market Access, Institutional Affairs, or similar role within the pharmaceutical or biotechnology industry.
- Strong understanding of the Italian healthcare system and regional access environment.
- Demonstrated ability to engage and influence regional healthcare stakeholders and decision-makers.
- Strong relationship-building, negotiation, and communication skills.
- Ability to work autonomously, prioritize effectively, and manage a geographically dispersed territory.
- Professional proficiency in Italian and good command of English.
- Develop and execute regional market access strategies aligned with national objectives.
- Build and maintain strong relationships with regional healthcare authorities, decision-makers, clinicians, patient associations, and other relevant stakeholders.
- Support the inclusion of CSL products within regional formularies and patient access pathways.
- Monitor regional healthcare policies, reimbursement frameworks, regulations, and funding decisions to assess business impact and identify opportunities.
- Contribute to regional tender activities and support initiatives that facilitate patient access to CSL therapies.
- Collaborate closely with Commercial, Medical Affairs, Tender, and Market Access colleagues to develop and implement regional plans.
- Provide insights on healthcare policy developments, stakeholder priorities, and regional access dynamics to support business decision-making.
- Experience in rare diseases, hemophilia, immunology, or specialty care.
About the company
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Get referred to CSL
See people who can refer or advise you
Simplify's Take
What believers are saying
- CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
- US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
- VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.
What critics are saying
- FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
- CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
- The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.
What makes CSL unique
- CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
- Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
- HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- 401(k) Retirement Plan
- 401(k) Company Match
- Paid Time Off
- Paid Vacation
- Paid Sick Leave
- Paid Holidays